Recent developments in the treatment of hypertriglyceridemia

Area of Science:

• Cardiology
• Metabolic Syndrome
• Pharmacology

Background:

• Hypertriglyceridemia is an independent risk factor for coronary artery disease (CAD).
• Targeting fasting triglycerides below 150 mg/dL is suggested for secondary CAD prevention.
• Statins can effectively lower high triglyceride levels.

Purpose of the Study:

• To review the impact of triglyceride-lowering therapies on coronary artery disease.
• To assess the role of fibrates, statins, and fish oils in CAD prevention.
• To identify areas for further clinical research in managing hypertriglyceridemia and CAD.

Main Methods:

• Review of secondary prevention trials involving fibrates (LOCAT, BECAIT, BIP).
• Analysis of studies on gemfibrozil (VA-HIT) and fish oils (GISSI) in CAD mortality.
• Examination of statin's efficacy in reducing triglyceride levels.

Main Results:

• Fibrates slow coronary artery luminal narrowing by reducing triglycerides and increasing HDL cholesterol.
• Gemfibrozil and fish oils decreased CAD mortality in secondary prevention.
• Statins are effective in significantly reducing high triglyceride levels.

Conclusions:

• Reducing triglycerides and increasing HDL cholesterol shows promise in slowing CAD progression.
• Further studies are required to confirm the mortality benefits of triglyceride reduction in secondary CAD prevention.
• The pharmacological benefit of drastic triglyceride reduction in primary prevention remains to be proven.